Core B, Tissue Bank provides the infrastructure to transport, receive, process, store, and distribute tissue specimens obtained from patients with myeloproliferative neoplasms (MPN) as well as patients enrolled on clinical trials (Project 4). These specimens are provided to MPN-RC investigators performing translational research for the purpose of developing innovative therapies (Projects1-3) and to the Biomarker & Bioinformatics Core D to perform biomarker analyses to evaluate the effectiveness of specific therapies to deplete MPN hematopoietic stem and progenitor cells (HSC/HPC). Tissues are also available to members of the scientific community at large for translational research. Translational research is dependent on the ready availability of tissues from a sufficient number of accurately diagnosed patients to generate statistically significant data. Because the MPNs are relatively uncommon and their accurate diagnosis can be difficult, there has been a paucity of tissue, linked to clinical data, available to individual investigators at single institutions. Core B fills this void. With an inventory of more than 15000 specimens from more than 1500 individual patients with MPNs, Core B maintains one of the world's largest inventories of MPN tissues available for research. In addition, Core B collects specimens from patients participating in MPN-RC sponsored clinical trials (Project 4) for the purpose of performing biomarker studies to demonstrate the effectiveness of specific therapies on the depletion of MPN hematopoietic stem and progenitor cells (HSC/HPC).
The specific aims of Tissue Bank Core B are to: 1) Receive, process, cryopreserve, and store tissues from MPN patients as well as patients enrolled on clinical trials (Project 4) at MPN-RC clinical sites; 2) Provide a central repository for MPN tissues that are associated with basic data stored in the web-based data bank maintained by Biostatistics and Data Management Core C including clinical, and laboratory data that enable selection and distribution of tissues best suited for each translational research project; 3) Distribute tissues to: MPN Consortium investigators for translational research to develop innovative therapies; MPN Consortium investigators to analyze biomarkers to determine therapeutic and pharmacodynamic response to therapy as well as to predict disease progression; and scientific community at large for translational research. Tissues are available to members of the MPN Research Consortium (MPN-RC) and to the scientific community at large for the performance of translational research. Core B is an essential shared resource that enables translational research that will ultimately lead to the development of molecularly targeted therapies.

Public Health Relevance

MPN-RC investigators are performing translational research in order to develop treatments and cures for myeloproliferative neoplasms (MPN) which are blood cancers. This research requires tissue specimens from patients with these diseases. MPN patients donate blood, bone marrow and spleen tissue to be used for research. The tissues are shipped to Core B Tissue Bank where they are processed, stored and then distributed to scientists for research purposes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA108671-10A1
Application #
9416777
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-03-01
Budget End
2019-02-28
Support Year
10
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029
Migliaccio, Anna Rita; Uversky, Vladimir N (2018) Dissecting physical structure of calreticulin, an intrinsically disordered Ca2+-buffering chaperone from endoplasmic reticulum. J Biomol Struct Dyn 36:1617-1636
Peeken, Jan C; Jutzi, Jonas S; Wehrle, Julius et al. (2018) Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms. Blood 131:2065-2073
Wang, Xiaoli; Hu, Cing Siang; Petersen, Bruce et al. (2018) Imetelstat, a telomerase inhibitor, is capable of depleting myelofibrosis stem and progenitor cells. Blood Adv 2:2378-2388
Zimran, Eran; Tripodi, Joseph; Rampal, Raajit et al. (2018) Genomic characterization of spleens in patients with myelofibrosis. Haematologica 103:e446-e449
Kleppe, Maria; Koche, Richard; Zou, Lihua et al. (2018) Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. Cancer Cell 33:785-787
Qiu, Jiajing; Salama, Mohamed E; Hu, Cing Siang et al. (2018) The characteristics of vessel lining cells in normal spleens and their role in the pathobiology of myelofibrosis. Blood Adv 2:1130-1145
Pronier, Elodie; Cifani, Paolo; Merlinsky, Tiffany R et al. (2018) Targeting the CALR interactome in myeloproliferative neoplasms. JCI Insight 3:
Migliaccio, Anna Rita (2018) A vicious interplay between genetic and environmental insults in the etiology of blood cancers. Exp Hematol 59:9-13
Gupta, Vikas; Kosiorek, Heidi E; Mead, Adam et al. (2018) Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study. Biol Blood Marrow Transplant :
Gnanapragasam, Merlin Nithya; Crispino, John D; Ali, Abdullah M et al. (2018) Survey and evaluation of mutations in the human KLF1 transcription unit. Sci Rep 8:6587

Showing the most recent 10 out of 195 publications